AbbVie’s Produodopa approved by SMC to treat Parkinson’s disease patients in Scotland The progressive neurological disorder affects approximately 12,400 people in Scotland
AbbVie’s Skyrizi shows promise as personalised treatment for psoriasis The immunosuppressant reduced inflammation in patients with the skin condition after three days